Ignite Creation Date:
2024-05-06 @ 1:38 AM
Last Modification Date:
2024-10-26 @ 11:07 AM
Study NCT ID:
NCT01869309
Status:
UNKNOWN
Last Update Posted:
2014-11-21
First Post:
2013-05-28
Brief Title:
Overcoming High On-Treatment Platelet Reactivity HPR During Prasugrel Therapy With Ticagrelor
Sponsor:
LifeBridge Health
Organization:
LifeBridge Health
Study Overview
Official Title:
Overcoming High On-Treatment Platelet Reactivity HPR During Prasugrel Therapy
Status:
UNKNOWN
Status Verified Date:
2013-12
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
HEIGHTEN
Brief Summary:
The primary objective is to determine the pharmacodynamic effect of ticagrelor dosing 180mg LD 90mg BID at 2 4 hours and 14 days in stable Coronary artery disease CAD patients who exhibit high-on prasugrel platelet reactivity defined as Vasodilator Stimulated Phosphoprotein-Phosphorylation VASP-P 50
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| ISSBRIL0149 | OTHER | AstaZeneca | None |